Go-CHOP as the Frontline Therapy for PTCL
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).
Peripheral T Cell Lymphoma
DRUG: Golidocitinib|DRUG: CHOP Regimen
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], TEAE, lab test, From first dose till 28 days post the last dose
Complete Response Rate, Complete response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria, From date of enrollment (first dose) until the end of induction therapy completed (~ 18 weeks)|Objective Response Rate, Objective response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria., From date of enrollment (first dose) until the end of induction therapy completed (~ 18 weeks)|Progression Free Survival, Objective response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria., From date of enrollment (first dose) until documented disease progression or death of any reason (up 2 year)|Duration of Response, Duration of response assessed by investigator per Lugano 2014 criteria, from first documented response till disease progression or death of any reason (up to 2 years)
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).